Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609.
Journal: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
Published: August 02, 2022
Effect of risk-reducing salpingo-oophorectomy on sex steroid hormone serum levels among postmenopausal women: an NRG Oncology/Gynecologic Oncology Group study.
Journal: American journal of obstetrics and gynecology
Published: November 22, 2021
Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses.
Journal: Journal for immunotherapy of cancer
Published: December 01, 2017
Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma.
Journal: Melanoma research
Published: November 28, 2017
Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA).
Journal: International journal of radiation oncology, biology, physics
Published: April 02, 2017
The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases.
Journal: International journal of radiation oncology, biology, physics
Published: January 17, 2017
Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study.
Journal: Journal for immunotherapy of cancer
Published: December 20, 2015
Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial.
Journal: Annals of surgical oncology
Published: July 06, 2015
Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment.
Journal: Cancer biotherapy & radiopharmaceuticals
Published: June 18, 2015
Last Updated: 09/26/2026